Drug intelligence / Profile preview

Doloteffin

Development stage
Unknown
Lead developer
Ardeypharm
Modality
Small Molecules
Administration
Oral
01

Overview

Doloteffin is a phyto-pharmaceutical (herbal extract) developed and marketed by Ardeypharm GmbH. The active ingredient is a dry extract derived from the secondary storage roots of *Harpagophytum procumbens* (devil's claw), standardized to contain the iridoid glycoside harpagoside as its primary active constituent. It is indicated for the treatment of painful musculoskeletal conditions, including osteoarthritis, lower back pain, and other inflammatory joint disorders. The therapeutic effect is attributed to the anti-inflammatory and analgesic properties of its constituents, which modulate inflammatory mediators such as leukotrienes and cytokines. Doloteffin is administered orally as film-coated tablets and is available in Germany as an approved medicinal product for locomotor and skeletal diseases.

Brand names
Doloteffin
Other names
Devil's claw extractHarpagophytum procumbens root extractHarpagophytum

Beyond the preview

Go deeper on Doloteffin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Doloteffin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call